- Published Articles
- In the Press
- Press Releases
Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
November 28th, 2016
FTC Policy Statement Focuses on Homeopathic Health Claims
Last week, the Federal Trade Commission issued its new "Enforcement Policy Statement on Marketing Claims for Over-the-Counter (OTC) Homeopathic Drugs," as well as a staff report on a workshop that the Commission held last year on OTC homeopathic drug advertising. As many know, homeopathy is an alternative medical system from the 1700s based on the idea that substances causing disease indications in healthy people can cure similar symptoms in sick people. According to the FTC's Policy Statement, many of the claims currently in circulation for OTC homeopathic products actually derive from longstanding homeopathic theories, and not from valid or modern efficacy studies using up-to-date scientific methods. The FTC is therefore concerned that much of the current advertising for OTC homeopathic products is misleading or deceptive, in violation of Section 5 of the FTC Act.
The Policy Statement is the most recent development in the homeopathic product arena, currently jointly regulated and monitored by the FTC and the FDA, and is yet another indication of the current regulatory focus on health claims. Other recent examples include: Food for Thought: FDA Will Reconsider Rules Governing Use of "Healthy" on Labels; the FTC's recent warning letters on anti-Zika health claims; its $1.35 million settlement with Tommie Copper, which focused on allegedly misleading pain relief claims for the company's copper-infused compression wear; its settlements with two companies that said their apps could detect symptoms of melanoma; and the pending action against the marketer of Elimidrol, announced as part of a joint law enforcement sweep with the Department of Justice, FDA, and others, challenging representations that the supplement substantially reduces symptoms from opiate withdrawal. Marketers of OTC homeopathic products should take heed.
By issuing this Policy Statement, the FTC now makes clear its intention to treat OTC homeopathic drugs no differently than other advertised health products. The Commission therefore requires that all disease claims for OTC homeopathic drugs be substantiated by competent and reliable scientific evidence. As the Policy Statement makes clear, OTC homeopathic advertising based on traditional theories of homeopathy may still pass muster as long it effectively communicates to consumers that there is no current scientific evidence of efficacy, or that the science supporting the claim is not routinely accepted in modern medicine. In such cases, the FTC will require inclusion of clear, prominent and non-perfunctory disclosures explaining the limited evidence supporting the efficacy of the homeopathic product. As the FTC notes:
• Any such disclosure should stand out and be in close proximity to the efficacy message; to be effective, it may actually need to be incorporated into the efficacy message.
• Marketers should not undercut qualifications with additional positive statements or consumer endorsements reinforcing a product's efficacy.
• There is an inherent contradiction in asserting that a product is effective and also disclosing that there is no scientific evidence for such an assertion. Depending on how disclosures are presented, many will be insufficient to prevent consumer deception. Marketers are advised to develop extrinsic evidence, such as consumer surveys, to determine the net impressions communicated by their marketing materials.
• The Commission will carefully scrutinize the net impression of OTC homeopathic advertising or other marketing employing disclosures to ensure that it adequately conveys the extremely limited nature of the health claim being asserted. If, despite a marketer's disclosures, an ad conveys more substantiation than the marketer has, the marketer will be in violation of the FTC Act.
We will continue to monitor regulation of health and safety claims, and to provide updates. If you have any questions about health claims, homeopathic product advertising, or about any other advertising law issues, please contact Jeff Greenbaum at (212) 826 5525 or email@example.com, Terri Seligman at (212) 826 5580 or firstname.lastname@example.org, Hannah Taylor at (212) 705 4849 or email@example.com, or any other member of the Frankfurt Kurnit Advertising, Marketing & Public Relations Group.
Share This Page
Other Advertising Law Alerts
Get Ready for California’s New “Automatic Renewal” Rules
California recently amended its Automatic Purchase Renewals law. The amended statute - effective July 1st -- require marketers to provide consumers of automatic renewal or continuous service offers with more information and easier ways to terminate. Read more.
June 22 2018
“Made in the U.S.A.” Claims Continue to be Scrutinized
In 2016, California amended Section 17533.7 of the California Business and Professions Code ("Section 17533"), liberalizing the standard for selling products labeled "Made in U.S.A" to California consumers. Read more.
June 4 2018
FTC Issues a $2 Million Reminder to Ad Agencies
The Federal Trade Commission ("FTC") and the State of Maine have announced a $2 million dollar settlement with ad agency Marketing Architects, Inc. ("MAI") for deceptive weight-loss claims. Read more.
February 12 2018